IL17A and Alzheimer disease: Biologic therapies may exacerbate this imbalance by selectively inhibiting one immune axis, thereby shifting the polarization—for example, IL-17A blockade favoring Th2 responses and potentially triggering AD, while Th2 blockade with dupilumab may promote Th17-driven psoriatic manifestations [21].